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Abstract This study analyzed the macrostructure and
microstructure of sleep in 12 parkinsonian patients under
basal conditions (T0) and during 1-night treatment (T1) with
a new formulation of apomorphine. This new formulation
consisted in a microemulsion of apomorphine administered
by the transdermal route, able to provide a constant release
of the drug over several hours (APO-TD). Sleep analysis at
T1 compared with T0 revealed a 16% increment of total
sleep time, a 12% increment of sleep efficiency, a 16% incre-
ment of stage 3 and 4 non-REM sleep, a 15% reduction of
periodic limb movements index, a 22% reduction of arousal
index, and a 23% reduction of cycling alternating
patterns/non-REM. We conclude that APO-TD may be able
to reduce nocturnal anomalous movements, akinesia, and
rigidity in Parkinson’s disease, and may reduce the disturbed
sleep typical of Parkinson’s disease.
Introduction
Sleep in Parkinson’s disease is frequently disrupted. There
may be several anomalous movements, such as periodic limb
movements (PLMs), persistence of tremor and prolonged
tonic contractions of limb muscles during non-REM sleep,
prolonged elevations in muscle tone during REM sleep,
REM behavior disorders, and reduction of normal body
shifts during sleep. These sleep disorders may lead to awak-
ening and microarousal, and may cause sleep fragmentation
and excessive daytime somnolence [1, 2]. Analysis of sleep
microstructure, including cycling alternating patterns (CAP),
may provide an index of sleep maintenance and is an objec-
tive measure of disruption of sleep [3, 4].
The aim of this study was to analyze the anomalous
movements during sleep and the alterations of sleep
microstructure (CAP sequence analysis, microarousals) in a
group of parkinsonian patients during 1-night treatment with
a new formulation of apomorphine. This new formulation is
a microemulsion-based drug delivery system, administered
by an epicutaneous-transdermal route (APO-TD). This for-
mulation provides a constant release of the drug for several
hours, as demonstrated in vitro with hairless mouse skin [5],
and may become particularly useful for night treatment of
motor fluctuation in parkinsonian patients.
Materials and methods
We selected 12 consecutive patients with idiopathic Parkinson’s
disease, according to the following inclusion criteria: age between
55 and 75 years, stage III–IV Hoehn-Yahr, presence of long-term L-
dopa syndrome characterized by “wearing-off” or predictable “off”
periods, and a positive response to subcutaneous apomorphine test
without severe side effects. The mean age was 62.3 years, the mean
duration of illness 6.3 years, and the mean Hoehn-Yahr stage 3.2.
The daily mean L-dopa dosage was 584 mg.
The patients underwent standard polysomnography under basal
conditions (T0) and during nocturnal treatment with 50 mg of APO-
TD applied to a 100-cm2 cutaneous area on the chest, from 10 p.m.
until 8. a.m. (T1). During this period blood samples were collected
at 3-h intervals from 10 p.m. for 12 h. The apomorphine concentra-
tion was then analyzed by high-performance liquid chromatogra-
phy. Anomalous sleep movements, and macrostructure and
microstructure of sleep were analyzed; CAP rate (total CAP
time/total non-REM time) was calculated.
Results
Pharmacokinetic analysis confirmed the absorption of apo-
morphine and the maintenance of therapeutic plasma levels
for several hours (mean Cmax 31.8±9.7 ng/ml, mean Tmax
3.1±1.6 h, mean half-life absorption 1.2±1.4 h, mean half-
life of elimination 8.8±1.9 h).
Sleep macrostructure analysis at T1 compared with T0
showed a 5% reduction of sleep onset latency (not signifi-
cant), a 16% increment of total sleep time (p=0.03), a 12%
increment of sleep efficiency (p=0.04), and a 16% increment
of stage 3–4 non-REM duration (p=0.04). In contrast, no
variation of stage 1–2 non-REM and REM phase duration
was noticed.
Persistence of tremor and prolonged tonic contractions of
limb muscles during non-REM 1–2 sleep stages were present
in a high percentage of patients (75% and 83.3%, respec-
tively). All patients showed a reduction of these disorders at
T1 compared with T0, although statistical significance was
not reached; 66.6% of patients presented PLMs. In these
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patients, the PLMs index and the PLMs index associated
with arousals showed a significant reduction at T1 compared
with T0 (15%, p=0.03 and 17%, p=0.02, respectively).
Apnea/hypopnea index was below 5 at T0 in all patients, and
did not show any significant variation at T1. Interestingly,
during APO-TD treatment, arousal index and CAP rate/non-
REM showed a significant reduction (22%, p=0.03 and 23%,
p=0.01, respectively). Body shifts appeared to be increased
(5%), but this variation did not reach statistical significance.
In our study APO-TD overall tolerability was good. No hal-
lucinations, vivid dreams, or nightmares occurred. Only 1
patient on awakening the following morning presented tran-
sient nausea controlled with domperidone. Five patients had
a transient mild erythema at the site of APO-TD application,
with complete regression within 48 h.
Discussion
Our study suggests that APO-TD treatment during the night
may reduce anomalous sleep movements in Parkinson’s dis-
ease. In our group of patients, persistence of tremor and pro-
longed tonic contractions of limb muscles during non-REM
sleep were reduced, while body shifts were increased. This
may be due to the prolonged dopaminergic stimulation pro-
vided by APO-TD, with a reduction of akinesia and rigidity
during the night hours. Similarly the PLMs index showed a
significant decrease, thus reducing one of the possible
sources of broken sleep, as demonstrated by the reduction of
the PLMs index associated with arousals.
This improvement of motor conditions during sleep may
explain the significant decrease in the arousal index and
CAP rate/non-REM, and the significant increment of sleep
stage 3–4 non-REM and sleep efficiency. In particular, the
CAP rate/non-REM decrease may be considered an objective
index of the reduction of sleep instability in these patients.
In conclusion, our study suggests that nocturnal trans-
dermal slow-release apomorphine treatment in Parkinson’s
disease, giving a constant absorption of the drug for at least
12 h, may be able to reduce nocturnal anomalous move-
ments, akinesia, and rigidity. Hence it may be efficacious in
reducing sleep instability typical of the fragmented parkin-
sonian sleep.
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Fig. 1 Nocturnal anomalous
movements reduction and sleep
microstructure analysis during
APO-MT treatment (T1) com-
pared to basal condition (T0).
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